These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 20709407

  • 1. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
    Ferreri AJ, Govi S, Colucci A, Crocchiolo R, Modorati G.
    Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
    [Abstract] [Full Text] [Related]

  • 2. Conjunctival and orbital lymphoma.
    Shinder R.
    Ophthalmology; 2011 Aug; 118(8):1692; author reply 1692, 1692.e1. PubMed ID: 21813098
    [No Abstract] [Full Text] [Related]

  • 3. Rituximab immunotherapy for ocular adnexal lymphoma: clinicopathologic correlation with 5-year follow-up.
    Sokol JA, Landau L, Lauer SA.
    Ophthalmic Plast Reconstr Surg; 2009 Aug; 25(4):322-4. PubMed ID: 19617799
    [Abstract] [Full Text] [Related]

  • 4. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva.
    Nückel H, Meller D, Steuhl KP, Dührsen U.
    Eur J Haematol; 2004 Oct; 73(4):258-62. PubMed ID: 15347312
    [Abstract] [Full Text] [Related]

  • 5. Intralesional Rituximab Injection for Low-Grade Conjunctival Lymphoma Management.
    Demirci H, Ozgonul C, Diniz Grisolia AB, Elner VM.
    Ophthalmology; 2020 Sep; 127(9):1270-1273. PubMed ID: 32336490
    [No Abstract] [Full Text] [Related]

  • 6. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K, Prins C, Saurat JH, French LE.
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [Abstract] [Full Text] [Related]

  • 7. Intralesional rituximab for primary iris lymphoma.
    Demirci H, Grant JS, Elner VM.
    JAMA Ophthalmol; 2015 Jan; 133(1):104-5. PubMed ID: 25211092
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Outcome and prognostic factors in ocular adnexal lymphoma.
    Nola M, Lukenda A, Bollmann M, Kalauz M, Petrovecki M, Bollmann R.
    Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM, Watier H, Paintaud G, de Muret A, Vaillant L, Machet L.
    Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
    [Abstract] [Full Text] [Related]

  • 12. Treatment of conjunctival mucosa-associated lymphoid tissue lymphoma with intralesional injection of interferon alfa-2b.
    Lachapelle KR, Rathee R, Kratky V, Dexter DF.
    Arch Ophthalmol; 2000 Feb; 118(2):284-5. PubMed ID: 10676800
    [No Abstract] [Full Text] [Related]

  • 13. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
    Maeshima AM, Taniguchi H, Fukuhara S, Morikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Tsuda H.
    Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bilateral conjunctival follicular lymphoma in a child.
    Wall PB, Traboulsi EI, Hsi ED, Singh AD.
    J AAPOS; 2015 Apr; 19(2):183-5. PubMed ID: 25824110
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. MALT lymphoma of the lacrimal gland in the context of systemic lupus erythematosus: complete remission after treatment with rituximab.
    Tektonidou MG.
    Lupus; 2010 Sep; 19(10):1243-5. PubMed ID: 20501524
    [Abstract] [Full Text] [Related]

  • 18. Intralesional interferon-α for the treatment of bilateral conjunctival mucosa-associated lymphoid tissue lymphoma.
    Holds J, Buchanan A, Hanson R.
    Pediatr Blood Cancer; 2012 Jul 15; 59(1):176-8. PubMed ID: 21793177
    [Abstract] [Full Text] [Related]

  • 19. Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.
    Duman BB, Sahin B, Ergin M, Guvenc B.
    Med Oncol; 2012 Jun 15; 29(2):1223-6. PubMed ID: 21805377
    [Abstract] [Full Text] [Related]

  • 20. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T, Jaén-Martínez J, Gumá-Padró J, Bosch-Príncep R, Salvadó-Usach MT.
    Ann Hematol; 2003 Sep 15; 82(9):585-8. PubMed ID: 12898184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.